地西他滨联合HAG方案治疗骨髓增生异常综合征的临床疗效及其安全性评价

目的 探讨地西他滨联合HAG方案治疗骨髓增生异常综合征的临床疗效及其安全性评价。方法 选择2014年8月-2016年8月在南阳市第二人民医院治疗的骨髓增生异常综合征患者56例，随机分为两组，对照组26例，接受HAG化疗，观察组30例患者，接受地西他滨联合HAG化疗，比较两组患者的临床疗效以及不良反应的发生情况。结果 第1个疗程结束后，对照组患者的总缓解率为26.9%，观察组为30.0%，虽然观察组的缓解率较高，但是统计分析差异并不显著。两个疗程结束后，观察组的总缓解率为83.3%，显著高于对照组患者的57.7%，差异有统计学意义（P<0.05）。观察组发生25例次不良反应，显著低于对照组（43例次），差异有统计学意义（P<0.05）。结论 地西他滨辅助治疗可以显著改善HAG化疗治疗骨髓增生异常综合征的临床疗效，降低化疗期间不良反应的发生率，提高患者的生活质量，值得临床推广应用。

Curative effect and safety of decitabine combined with HAG for patients with myelodysplastic syndromes

Objective To explore the curative effect and safety of decitabine combined with HAG for patients with myelodysplastic syndromes. Methods Fifty-six patients with myelodysplastic syndromes in Nanyang Second General Hospital from August 2014 to August 2016 were divided randomly into control group (n=26, accepted HAG chemotherapy) and study group (n=30, adopted decitabine combined with HAG) to compare the clinical curative and the incidence of adverse reactions between two groups. Results After a course of treatment, the total remission of control group was 26.9%, and study group was 30%, and difference was no significance between two groups. After two courses of treatment, the total remission of study group (83.3%) was higher significantly than those of control group (57.7%). The case of adverse reactions of study group (25 cases) was lower than control group significantly (P<0.05). Conclusions Decitabine assisted HAG chemotherapy could improve the clinical curative effect remarkably for patients myelodysplastic syndromes, which deserved popularization in clinic duo to the decreasing incidence of adverse reactions and the well quality of life.